Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
7.33 BRL | +2.23% | +1.95% | -9.42% |
03-07 | Transcript : Dexco S.A., Q4 2023 Earnings Call, Mar 07, 2024 | |
03-07 | Dexco S.A. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 | CI |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
- According to Refinitiv, the company's ESG score for its industry is good.
Strengths
- The company appears to be poorly valued given its net asset value.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
- The company is in debt and has limited leeway for investment
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The company is not the most generous with respect to shareholders' compensation.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Forest & Wood Products
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-9.42% | 1.15B | A- | ||
+5.28% | 5.39B | B- | ||
-17.29% | 1.7B | C | ||
+6.46% | 1.38B | A- | ||
+17.95% | 1.19B | - | ||
-7.86% | 748M | - | ||
-20.93% | 704M | B- | ||
+6.09% | 532M | C- | ||
-16.38% | 505M | - | ||
-25.90% | 467M | D+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- DXCO3 Stock
- Ratings Dexco S.A.